Sign In
Buy AERI
$15.25
+0 (+0%)
At Close: Feb 17, 2023
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
04:30pm, Tuesday, 09'th Nov 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
Aerie Pharmaceuticals' (AERI) Management on Q3 2021 Results - Earnings Call Transcript
05:30am, Sunday, 07'th Nov 2021
Aerie Pharmaceuticals' (AERI) Management on Q3 2021 Results - Earnings Call Transcript
Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y
12:13pm, Friday, 05'th Nov 2021
Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
06:19pm, Thursday, 04'th Nov 2021
Aerie (AERI) delivered earnings and revenue surprises of -16.13% and 0.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan
06:30am, Tuesday, 12'th Oct 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company's Phase 3 clinical trial in Japa
Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase
04:01pm, Thursday, 07'th Oct 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an ove
Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists
07:30am, Wednesday, 06'th Oct 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal impla
Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference
07:30am, Monday, 27'th Sep 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO
06:30am, Tuesday, 21'st Sep 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman
Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Disposition
06:30am, Monday, 20'th Sep 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications
06:30am, Monday, 13'th Sep 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies f
Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences
07:30am, Tuesday, 07'th Sep 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference
07:30am, Thursday, 12'th Aug 2021
DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q2 2021 Results - Earnings Call Transcript
11:54pm, Wednesday, 04'th Aug 2021
Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q2 2021 Results - Earnings Call Transcript
